Oliver Gimm

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2420642/publications.pdf

Version: 2024-02-01

		182225	104191
75	5,629	30	69
papers	citations	h-index	g-index

79	79	79	4766
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Voice Changes Without Laryngeal Nerve Alterations After Thyroidectomy: The Need For Prospective Trials - A Review Study. Journal of Voice, 2024, 38, 231-238.	0.6	2
2	Genetic Alterations in Mitochondrial DNA Are Complementary to Nuclear DNA Mutations in Pheochromocytomas. Cancers, 2022, 14, 269.	1.7	3
3	Loss of SDHB Induces a Metabolic Switch in the hPheo1 Cell Line toward Enhanced OXPHOS. International Journal of Molecular Sciences, 2022, 23, 560.	1.8	8
4	GBS-MeDIP: A protocol for parallel identification of genetic and epigenetic variation in the same reduced fraction of genomes across individuals. STAR Protocols, 2022, 3, 101202.	0.5	4
5	X-chromosome variants are associated with aldosterone producing adenomas. Scientific Reports, 2021, 11, 10562.	1.6	2
6	Increased diagnostic sensitivity of palpationâ€guided thyroid nodule fineâ€needle aspiration cytology by BRAF V600E â€mutation analysis. Journal of Pathology: Clinical Research, 2021, 7, 556-564.	1.3	3
7	Activation of RAS Signalling is Associated with Altered Cell Adhesion in Phaeochromocytoma. International Journal of Molecular Sciences, 2020, 21, 8072.	1.8	5
8	Dual energy 4D-CT of parathyroid adenomas not clearly localized by sestamibi scintigraphy and ultrasonography â€“ a retrospective study. European Journal of Radiology, 2020, 124, 108821.	1.2	11
9	Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study. European Journal of Endocrinology, 2020, 183, 453-462.	1.9	18
10	Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. Journal of Internal Medicine, 2019, 285, 187-204.	2.7	83
11	Management of incidental gallbladder cancer in a national cohort. British Journal of Surgery, 2019, 106, 1216-1227.	0.1	27
12	Training in endocrine surgery. Langenbeck's Archives of Surgery, 2019, 404, 929-944.	0.8	13
13	Challenges of training in adrenal surgery. Gland Surgery, 2019, 8, S3-S9.	0.5	10
14	Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior. American Journal of Surgical Pathology, 2019, 43, 409-421.	2.1	24
15	A somatic mutation in CLCN2 identified in a sporadic aldosterone-producing adenoma. European Journal of Endocrinology, 2019, 181, K37-K41.	1.9	54
16	Extent of surgery for phaeochromocytomas in the genomic era. British Journal of Surgery, 2018, 105, e84-e98.	0.1	31
17	M2-macrophage infiltration and macrophage traits of tumor cells in urinary bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 159.e19-159.e26.	0.8	32
18	Are Incidental Gallbladder Cancers Missed with a Selective Approach of Gallbladder Histology at Cholecystectomy?. World Journal of Surgery, 2018, 42, 1092-1099.	0.8	39

#	Article	IF	Citations
19	Activating FGFR1 Mutations in Sporadic Pheochromocytomas. World Journal of Surgery, 2018, 42, 482-489.	0.8	13
20	The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 530.e7-530.e18.	0.8	15
21	65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocrine-Related Cancer, 2018, 25, T201-T219.	1.6	52
22	Preventive medicine of von Hippelâ€“Lindau disease-associated pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 783-793.	1.6	42
23	Radioâ€guided sentinel lymph node detection and lymph node mapping in invasive urinary bladder cancer: a prospective clinical study. BJU International, 2017, 120, 329-336.	1.3	24
24	Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention. JAMA Oncology, 2017, 3, 1204.	3.4	149
25	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nature Reviews Endocrinology, 2017, 13, 233-247.	4.3	198
26	The Transcriptional Regulation of FOXO Genes in Thyrocytes. Hormone and Metabolic Research, 2016, 48, 601-606.	0.7	10
27	Genetics of primary hyperaldosteronism. Endocrine-Related Cancer, 2016, 23, R437-R454.	1.6	28
28	<scp>HRAS</scp> mutation prevalence and associated expression patterns in pheochromocytoma. Genes Chromosomes and Cancer, 2016, 55, 452-459.	1.5	28
29	Absence of the BRAF V600E mutation in pheochromocytoma. Journal of Endocrinological Investigation, 2016, 39, 715-716.	1.8	3
30	Wholeâ€exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT 2 D as a recurrently mutated gene. Genes Chromosomes and Cancer, 2015, 54, 542-554.	1.5	57
31	Rare Germline Mutations Identified by Targeted Next-Generation Sequencing of Susceptibility Genes in Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1352-E1360.	1.8	145
32	Frequent EPAS1/HIF2Î± exons 9 and 12 mutations in non-familial pheochromocytoma. Endocrine-Related Cancer, 2014, 21, 495-504.	1.6	67
33	Complementary somatic mutations of KCNJ5, ATP1A1, and ATP2B3 in sporadic aldosterone producing adrenal adenomas. Endocrine-Related Cancer, 2014, 21, L1-L4.	1.6	25
34	Role of SDHAF2 and SDHD in von Hippelâ€“Lindau Associated Pheochromocytomas. World Journal of Surgery, 2014, 38, 724-732.	0.8	6
35	Extent of surgery in clinically evident but operable MTC â€“ when is central and/or lateral lympadenectomy indicated?. Thyroid Research, 2013, 6, S3.	0.7	11
36	Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Human Molecular Genetics, 2012, 21, 5406-5416.	1.4	97

#	Article	IF	Citations
37	Super-selective venous sampling in conjunction with quickPTH for patients with persistent primary hyperparathyroidism: report of five cases. Surgery Today, 2012, 42, 570-576.	0.7	11
38	Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbeck's Archives of Surgery, 2012, 397, 155-177.	0.8	39
39	Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocrine-Related Cancer, 2011, 18, R253-R276.	1.6	299
40	Biomarkers in Thyroid Tumor Research: New Diagnostic Tools and Potential Targets of Molecular-Based Therapy. Journal of Thyroid Research, 2011, 2011, 1-2.	0.5	7
41	Dual-Energy Computed Tomography Localizes Ectopic Parathyroid Adenoma. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3092-3093.	1.8	14
42	Limitations of Intraoperative Adrenal Remnant Volume Measurement in Patients Undergoing Subtotal Adrenalectomy. World Journal of Surgery, 2008, 32, 863-872.	0.8	41
43	Germline CDKN1B/p27Kip1 Mutation in Multiple Endocrine Neoplasia. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3321-3325.	1.8	262
44	GermlineNF1Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2784-2792.	1.8	126
45	Intra-operative quick insulin assay to confirm complete resection of insulinomas guided by selective arterial calcium injection (SACI). Langenbeck's Archives of Surgery, 2007, 392, 679-684.	0.8	19
46	Distinct Expression of Galectin-3 in Pheochromocytomas. Annals of the New York Academy of Sciences, 2006, 1073, 571-577.	1.8	7
47	Prognostic Significance of Disseminated Tumor Cells in the Connective Tissue of Patients with Medullary Thyroid Carcinoma. World Journal of Surgery, 2006, 30, 847-852.	0.8	11
48	Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 827-836.	1.8	560
49	Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx. Familial Cancer, 2005, 4, 17-23.	0.9	25
50	Frequent Promoter Methylation of Tumor-Related Genes in Sporadic and Men2-Associated Pheochromocytomas. Experimental and Clinical Endocrinology and Diabetes, 2005, 113, 1-7.	0.6	28
51	Repeat Adrenocortical-Sparing Adrenalectomy for Recurrent Hereditary Pheochromocytoma. Surgery Today, 2004, 34, 251-255.	0.7	31
52	Multiple Endocrine Neoplasia 2B Syndrome due to Codon 918 Mutation: Clinical Manifestation and Course in Early and Late Onset Disease. World Journal of Surgery, 2004, 28, 1305-1311.	0.8	97
53	Timing and Extent of Surgery in Patients with Familial Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia 2A-related RET Mutations Not Affecting Codon 634. World Journal of Surgery, 2004, 28, 1312-1316.	0.8	57
54	Functional Results After Endoscopic Subtotal Cortical-Sparing Adrenalectomy. Surgery Today, 2003, 33, 342-348.	0.7	33

#	Article	IF	Citations
55	Technical Aspects of Subtotal Endoscopic Adrenalectomy. European Surgery - Acta Chirurgica Austriaca, 2003, 35, 84-88.	0.3	9
56	Pattern of lymph node metastases in papillary thyroid carcinoma. British Journal of Surgery, 2003, 85, 252-254.	0.1	198
57	Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy. Surgery, 2003, 134, 1020-1027.	1.0	82
58	The Genetic Basis of Pheochromocytoma. , 2003, 31, 45-60.		51
59	Germ-Line Mutations in Nonsyndromic Pheochromocytoma. New England Journal of Medicine, 2002, 346, 1459-1466.	13.9	1,299
60	RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome?. Surgery, 2002, 132, 952-959.	1.0	58
61	Calcitonin kinetics in the early postoperative period of medullary thyroid carcinoma. Langenbeck's Archives of Surgery, 2001, 386, 434-439.	0.8	27
62	Cloning and characterization of the human GFRA2 locus and investigation of the gene in Hirschsprung disease. Human Genetics, 2001, 108, 409-415.	1.8	17
63	Over-representation of a germline variant in the gene encoding RET co-receptor GFRÎ±-1 but not GFRÎ±-2 or GFRÎ±-3 in cases with sporadic medullary thyroid carcinoma. Oncogene, 2001, 20, 2161-2170.	2.6	29
64	Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Human Molecular Genetics, 2001, 10, 251-258.	1.4	79
65	Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. , 2000, 88, 1909-1915.		128
66	Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. , 2000, 88, 1909.		7
67	Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer, 2000, 88, 1909-15.	2.0	30
68	Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Research, 2000, 60, 6822-5.	0.4	206
69	Repeat mediastinal lymph-node dissection for palliation in advanced medullary thyroid carcinoma. Langenbeck's Archives of Surgery, 1999, 384, 271-276.	0.8	22
70	Determinative Factors of Biochemical Cure after Primary and Reoperative Surgery for Sporadic Medullary Thyroid Carcinoma. World Journal of Surgery, 1998, 22, 562-568.	0.8	123
71	Prophylactic Thyroidectomy in 75 Children and Adolescents with Hereditary Medullary Thyroid Carcinoma: German and Austrian Experience. World Journal of Surgery, 1998, 22, 744-751.	0.8	193
72	Reoperation in metastasizing medullary thyroid carcinoma: Is a tumor stage-oriented approach justified?. Surgery, 1997, 122, 1124-1131.	1.0	64

#	Article	IF	Citations
73	Medullary thyroid cancer â€" Reoperation. Acta Chirurgica Austriaca, 1997, 29, 15-17.	0.2	1
74	Invited commentary to: â€œLong-term results of surgical therapy for hyperthyroidismâ€: Acta Chirurgica Austriaca, 1996, 28, 232-233.	0.2	0
75	Long-Term Outcome after Treatment of Endocrine Tumors. , 0, , 845-852.		0